BACKGROUND: Building on previous acceptability research undertaken in sub-Saharan Africa this article aims to investigate the acceptability of intermittent preventive treatment of malaria in infants (IPTi) in Papua New Guinea (PNG). METHODS: A questionnaire was administered to mothers whose infants participated in the randomised placebo controlled trial of IPTi. Mothers whose infants participated and who refused to participate in the trial, health workers, community reporters and opinion leaders were interviewed. Men and women from the local community also participated in focus group discussions. RESULTS: Respondents viewed IPTi as acceptable in light of wider concern for infant health and the advantages of trial participation. Mothers reported complying with at-home administration of IPTi due to perceived benefits of IPTi and pressure from health workers. In spite of patchy knowledge, respondents also demonstrated a demand for infant vaccinations and considered non-vaccination to be neglect. There is little evidence that IPTi has negative impacts on attitudes to EPI, EPI adherence or existing malaria prevention practices. CONCLUSION: The degree of similarity between findings from the acceptability studies undertaken in sub-Saharan Africa and PNG allows some generalization relating to the implementation of IPTi outside of Africa: IPTi fits well with local health cultures, appears to be accepted easily and has little impact on attitudes towards EPI or malaria prevention. The study adds to the evidence indicating that IPTi could be rolled out in a range of social and cultural contexts.
RCT Entities:
BACKGROUND: Building on previous acceptability research undertaken in sub-Saharan Africa this article aims to investigate the acceptability of intermittent preventive treatment of malaria in infants (IPTi) in Papua New Guinea (PNG). METHODS: A questionnaire was administered to mothers whose infants participated in the randomised placebo controlled trial of IPTi. Mothers whose infants participated and who refused to participate in the trial, health workers, community reporters and opinion leaders were interviewed. Men and women from the local community also participated in focus group discussions. RESULTS: Respondents viewed IPTi as acceptable in light of wider concern for infant health and the advantages of trial participation. Mothers reported complying with at-home administration of IPTi due to perceived benefits of IPTi and pressure from health workers. In spite of patchy knowledge, respondents also demonstrated a demand for infant vaccinations and considered non-vaccination to be neglect. There is little evidence that IPTi has negative impacts on attitudes to EPI, EPI adherence or existing malaria prevention practices. CONCLUSION: The degree of similarity between findings from the acceptability studies undertaken in sub-Saharan Africa and PNG allows some generalization relating to the implementation of IPTi outside of Africa: IPTi fits well with local health cultures, appears to be accepted easily and has little impact on attitudes towards EPI or malaria prevention. The study adds to the evidence indicating that IPTi could be rolled out in a range of social and cultural contexts.
Authors: Steven Toikilik; George Tuges; Jamie Lagani; Elis Wafiware; Enoch Posanai; Ben Coghlan; Christopher Morgan; Rohan Sweeney; Nan Miller; Anatoly Abramov; Anthony Stewart; C John Clements Journal: Vaccine Date: 2010-05-06 Impact factor: 3.641
Authors: D Schellenberg; C Menendez; E Kahigwa; J Aponte; J Vidal; M Tanner; H Mshinda; P Alonso Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: Lesong Conteh; Elisa Sicuri; Fatuma Manzi; Guy Hutton; Benson Obonyo; Fabrizio Tediosi; Prosper Biao; Paul Masika; Fred Matovu; Peter Otieno; Roly D Gosling; Mary Hamel; Frank O Odhiambo; Martin P Grobusch; Peter G Kremsner; Daniel Chandramohan; John J Aponte; Andrea Egan; David Schellenberg; Eusebio Macete; Laurence Slutsker; Robert D Newman; Pedro Alonso; Clara Menéndez; Marcel Tanner Journal: PLoS One Date: 2010-06-15 Impact factor: 3.240
Authors: John J Aponte; David Schellenberg; Andrea Egan; Alasdair Breckenridge; Ilona Carneiro; Julia Critchley; Ina Danquah; Alexander Dodoo; Robin Kobbe; Bertrand Lell; Jürgen May; Zul Premji; Sergi Sanz; Esperanza Sevene; Rachida Soulaymani-Becheikh; Peter Winstanley; Samuel Adjei; Sylvester Anemana; Daniel Chandramohan; Saadou Issifou; Frank Mockenhaupt; Seth Owusu-Agyei; Brian Greenwood; Martin P Grobusch; Peter G Kremsner; Eusebio Macete; Hassan Mshinda; Robert D Newman; Laurence Slutsker; Marcel Tanner; Pedro Alonso; Clara Menendez Journal: Lancet Date: 2009-09-16 Impact factor: 79.321
Authors: Norbert G Schwarz; Marjolein Gysels; Christopher Pell; Julian Gabor; Meike Schlie; Saadou Issifou; Bertrand Lell; Peter G Kremsner; Martin P Grobusch; Robert Pool Journal: Vaccine Date: 2009-07-17 Impact factor: 3.641
Authors: George Okello; Sarah N Ndegwa; Katherine E Halliday; Kara Hanson; Simon J Brooker; Caroline Jones Journal: Malar J Date: 2012-06-08 Impact factor: 2.979
Authors: Nicolas Senn; Patricia Rarau; Danielle I Stanisic; Leanne Robinson; Céline Barnadas; Doris Manong; Mary Salib; Jonah Iga; Nandao Tarongka; Serej Ley; Anna Rosanas-Urgell; John J Aponte; Peter A Zimmerman; James G Beeson; Louis Schofield; Peter Siba; Stephen J Rogerson; John C Reeder; Ivo Mueller Journal: PLoS Med Date: 2012-03-27 Impact factor: 11.069
Authors: Erin V W Andrew; Christopher Pell; Angeline Angwin; Alma Auwun; Job Daniels; Ivo Mueller; Suparat Phuanukoonnon; Robert Pool Journal: PLoS One Date: 2015-04-20 Impact factor: 3.240
Authors: Oriane Sottas; Monia Guidi; Benjamin Thieffry; Marie Schneider; Laurent Décosterd; Ivo Mueller; Blaise Genton; Chantal Csajka; Nicolas Senn Journal: PLoS One Date: 2019-02-06 Impact factor: 3.240
Authors: Maria Lahuerta; Roberta Sutton; Anthony Mansaray; Oliver Eleeza; Brigette Gleason; Adewale Akinjeji; Mohamed F Jalloh; Mame Toure; Getachew Kassa; Steven R Meshnick; Molly Deutsch-Feldman; Lauren Parmley; Michael Friedman; Samuel Juana Smith; Miriam Rabkin; Laura Steinhardt Journal: Malar J Date: 2021-02-06 Impact factor: 2.979